Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macitentan in Inoperable CTEPH (MERIT-1)
NCT02021292Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Aug 2014
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in chronic thromboembolic pulmonary hypertension (CTEPH) comparing Macitentan with Placebo (2 arms). Primary endpoint: Pulmonary Vascular Resistance at 16 weeks. Started Aug 2014; status: completed.
02
Drugs
macitentan
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NCT02021292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02021292.